SCHEMBL17520432

SCHEMBL17520432

CN1C(=O)N2Cc3c(c4ccccc4n3Cc3ccc(C(=O)NOC4CCCCO4)cc3)C(C2)C1=S

nearest known ligand 0.72

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ HDAC6 Q9UBN7 20/20 0.72
▸ HDAC2 Q92769 16/20 0.72
▸ HDAC8 Q9BY41 16/20 0.72
▸ HDAC3 O15379 1/20 0.60
▸ HDAC4 P56524 1/20 0.60
▸ HDAC1 Q13547 1/20 0.60
▸ HDAC7 Q8WUI4 1/20 0.60
▸ HDAC10 Q969S8 1/20 0.60
▸ HDAC11 Q96DB2 1/20 0.60
▸ HDAC5 Q9UQL6 1/20 0.60
▸ NCOR2 Q9Y618 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19138896 0.93 HDAC6 (0.71) HDAC6HDAC2HDAC8HDAC3HDAC4
SCHEMBL19161577 0.93 HDAC6 (0.71) HDAC6HDAC2HDAC8HDAC3HDAC4
SCHEMBL17520665 0.91 HDAC6 (0.73) HDAC6HDAC2HDAC8HDAC3HDAC4
SCHEMBL17520537 0.88 HDAC6 (0.70) HDAC6HDAC2HDAC8HDAC3HDAC4
SCHEMBL17520666 0.86 HDAC6 (0.57) HDAC6HDAC2HDAC8HDAC3HDAC4
SCHEMBL19168016 0.85 HDAC6 (0.58) HDAC6HDAC2HDAC8HDAC3HDAC4
SCHEMBL17520639 0.84 HDAC6 (1.00) HDAC6HDAC2HDAC8HDAC3HDAC4
SCHEMBL19138924 0.84 HDAC6 (0.72) HDAC6HDAC2HDAC8HDAC3HDAC4
SCHEMBL19138940 0.83 HDAC6 (0.76) HDAC6HDAC2HDAC8HDAC3HDAC4
SCHEMBL19138894 0.82 HDAC6 (0.74) HDAC6HDAC2HDAC8HDAC3HDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3177621-B1 NOVEL HDAC6 INHIBITORS AND THEIR USES UNIV REGENSBURG (DE) 2021-11-10 — — EP disclosed
EP-3177621-B1 NOVEL HDAC6 INHIBITORS AND THEIR USES UNIV REGENSBURG (DE) 2021-11-10 — — EP disclosed
US-10106540-B2 HDAC6 inhibitors and their uses UNIVERSITÄT REGENSBURG (DE) 2018-10-23 — — US disclosed
US-20170210743-A1 NOVEL HDAC6 INHIBITORS AND THEIR USES Universitätsklinikum Jena (DE) 2017-07-27 — — US disclosed
US-20170210743-A1 NOVEL HDAC6 INHIBITORS AND THEIR USES Universitätsklinikum Jena (DE) 2017-07-27 — — US disclosed
WO-2016020369-A1 NOVEL HDAC6 INHIBITORS AND THEIR USES UNIVERSITÄT REGENSBURG (DE) 2016-02-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170210743-A1 NOVEL HDAC6 INHIBITORS AND THEIR USES HDAC6, HDAC5, HDAC4 HDAC6 1/4885HDAC2 6/4885HDAC8 10/4885
US-10106540-B2 HDAC6 inhibitors and their uses HDAC6, HDAC5, HDAC4 HDAC6 1/4885HDAC2 6/4885HDAC8 9/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback